Effectiveness of intraosseous tranexamic acid combined with intravenous tranexamic acid in hip arthroplasty

Effectiveness of intraosseous tranexamic acid combined with intravenous tranexamic acid compared with single route of intravenous tranexamic acid in hip arthroplasty

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200511002

Enrollment

Registered

2020-05-11

Start date

2020-05-11

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of hip Osteoarthritis of hip Hip arthroplasty

Interventions

Patients received routine intravenous tranexamic acid 1g just before operation plus intraosseous tranexamic acid 1g (pour into femoral canal) intraoperative.,Patients received only routine intravenous

Experimental Drug,Active Comparator Drug

Combined TXA,IV TXA

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adult patients diagnoses as osteoarthritis of hip and undergoing cementless total hip arthroplasty

Exclusion criteria

Exclusion criteria: - Allergy to tranexamic acid - Coagulopathy - Severe renal impairment - History of venous thromboembolism - History of ischemic heart disease, ischemic stroke - History of seizure

Design outcomes

Primary

Measure	Time frame
Total blood loss from total hip arthroplasty 3 days Intraoperative blood loss+ Drainage+ Hb change	—

Secondary

Measure	Time frame
Complications : venous thromboembolism 1 week Monitor sign and symptoms of VTE, if suspect, then further investigations will be done.	—

Contacts

Public ContactNarathorn Kongsakpaisal

Faculty of Medicine, Chulalongkorn University

beam_narathorn@yahoo.com0897817666

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026